Neuro precision STALICLA is a Swiss clinical-stage biotech specializing in Neuro Precision Medicine for neurodevelopmental and neuropsychiatric disorders, presenting an opportunity to partner on biomarker-driven trials, companion diagnostics, and targeted patient subgroups in ASD and SUD.

Phase two readiness Current efforts include preparing Phase 2 trials for the ASD patient-subgroup matched treatment STP1, suggesting collaboration opportunities in trial design, biomarker validation, regulatory strategy, and strategic partnering for late-stage development.

Strategic partnerships Active collaboration with NIDA on cocaine use disorder trial programs indicates openness to research alliances, sponsored studies, and co-development arrangements with organizations focused on substance use and neuropsychiatric research.

Funding trajectory Recent financing rounds and leadership appointments signal a company in rapid growth and fundraising mode, presenting sales angles around strategic investments, licensing deals, and milestone-based partnerships with visibility into continued capital needs.

Clinical and platform breadth The integrated multi-omics DEPI platform for patient subgrouping and the broad neurodevelopmental initiative position STALICLA for partnerships in diagnostics, companion biomarkers, clinical trial optimization, and precision medicine tooling across ASD and SUD programs.